Search
With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases
- blonca9
- Sep 5, 2024
- 1 min read
CEO Stéphane Boissel describes the company's first gene therapy program, with seeks to treat retinitis pigmentosa regardless of the mutational cause, and the future of its CRISPR/Cas9 gene editing partnership with Intellia.